AI assistant
C4 Therapeutics, Inc. — Director's Dealing 2023
Aug 31, 2023
33861_dirs_2023-08-31_8758b8be-3c25-4210-9c20-d11a64697a3c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2023-08-30
Reporting Person: Boyle Scott N (Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-30 | Common Stock | M | 2250 | — | Acquired | 27426 | Direct |
| 2023-08-30 | Common Stock | F | 661 | $2.93 | Disposed | 26765 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-08-30 | Performance Restricted Stock Units | $ | M | 2250 | Disposed | 2025-02-28 | Common Stock (2250) | Direct |
Footnotes
F1: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.